Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF) has entered into an exclusive biomarker development agreement with Professor Robin Carhart-Harris, chair of TYP’s Scientific Advisory Board, and Professor Pedro Mediano of Imperial College London to develop a proprietary electroencephalogram (EEG)-based biomarker platform for its lead program, TRP-8803 (IV-infused psilocin).
The collaboration will leverage real-time cortical entropy research to predict and optimise therapeutic outcomes from TRP-8803. The biomarker platform will provide clinicians with a tool to identify patients most likely to benefit from psychedelic therapy and adjust dosing in real time to achieve the optimal neuroplasticity window.
Hertz Global (NYSE:HTZ) shares jumped more than 5% after it announced it has partnered with Amazon Autos to sell a portion of its used vehicle inventory through Amazon's automotive retail platform.
This deal marks the first time Amazon Autos will work with a fleet dealer, with Hertz Car Sales being the inaugural fleet partner.
Antimony has emerged as one of the most strategically important, and volatile, minerals of 2025. Used in everything from flame retardants to military-grade equipment and electric vehicle batteries, the metal now sits at the center of a global supply crisis that is driving prices to historic highs and raising alarms from the likes of the US Department of Defense and major battery manufacturers.
This year, prices for antimony have surged more than 800% compared to 2020 levels, largely attributed to a perfect storm of supply shocks, rising demand, and escalating geopolitical tensions. China, which dominates the global antimony supply chain with over 70% of worldwide production and most of the refining capacity, imposed tighter export controls in late 2024. In March 2025, it halted antimony exports altogether for a period, triggering immediate price spikes of 50% or more and introducing a two-tiered global pricing system. While domestic Chinese buyers continued to pay under $30,000 per ton, international buyers faced steep costs that are often double that amount. As a result, US battery makers, defense contractors, and auto suppliers have been forced to pay extreme premiums or turn to limited and unproven alternative sources.
Guess? (NYSE:GES) shares surged in early trade as the American clothing company revealed it will go private in a deal with Authentic Brands that values it at $1.4 billion.
The company said Guess? shareholders will receive $16.75 per share in cash, representing a premium of 73% from when the company first disclosed back in March that it had received an acquisition proposal from a third party.
Sonoro Gold Corp (TSX-V:SGO, OTCQB:SMOFF) is raising C$525,000 through a non-brokered private placement as it continues work on its Cerro Caliche gold project in Sonora, Mexico.
The Vancouver-based company said Wednesday it plans to issue 3.5 million units at $0.15 each.
Graphene Manufacturing Group Ltd (TSX-V:GMG, OTCQX:GMGMF) is raising fresh investment via a C$5 million bought deal, giving investors a new entry point into the Australia-based clean-tech firm as it works to commercialize its graphene-based products.
The company said Wednesday it has struck a deal with Red Cloud Securities to sell 5.56 million units at C$0.90 each.
Excellon Resources Inc (TSX:EXN, OTCQB:EXNRF) told investors it has now closed an offtake and financing agreement with Glencore subsidiaries to support the restart of the Mallay silver mine in Peru.
The Glencore facility provides up to US$7.5 million in the form of a pre-export finance loan, comprising an initial drawdown of up to US$5 million, and an optional US$2.5 million available until March 2026.
Baselode Energy Corp (TSX-V:FIND, OTCQB:BSENF) has moved a step closer to closing its all-share merger with Forum Energy Metals after Forum shareholders overwhelmingly backed the deal in a vote held Tuesday.
At a special meeting, 97.57% of Forum shareholders voted in favour of Baselode’s plan to acquire the company in an arrangement that will see Forum investors receive 0.3535 Baselode shares for each Forum share they hold.
Nano One Materials Corp (TSX:NANO, OTC:NNOMF) told investors it has installed and commissioned a proprietary agitator in the full‑scale One‑Pot reactor at its Candiac facility in Québec.
The upgrade is designed to improve cost performance and support scale‑up and product commercialization. The custom unit is fitted to a 20,000‑litre reactor.
Shares in OptiBiotix Health PLC (AIM:OPTI, OTC:OPBXF) rose as much as 9% on Wednesday after the company signed a distribution agreement with a major direct-selling weight management brand.
The AIM-listed life sciences group said it would supply SlimBiome products, designed to reduce hunger and food cravings, under the partner’s branding.
Shares in Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF) leapt 39% higher to 0.034p after saying that its Zulu lithium and tantalum project in Zimbabwe has into full operation.
This followed the successful completion of the second phase of plant testing.
Shares in Viking Therapeutics (NASDAQ:VKTX) ended a bloody session 42% lower after the US biotech released trial data on its experimental obesity pill that underwhelmed investors.
The phase two results showed patients lost up to 12.2 % of body weight after three months on the treatment, VK2735.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests.
The liquid biopsy specialist said on Wednesday that blood samples from cancer patients would be processed using its Parsortix system, which isolates whole cancer cells circulating in the bloodstream.
Research platform MST Access has raised its valuation on Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) following the company’s submission of a CLIA waiver application to the US Food & Drug Administration (FDA) for its flagship FebriDx point-of-care test.
Senior analyst Chris Kallos now values the company at A$223 million, or $0.22 per fully diluted share, up from A$176 million ($0.10). The higher valuation reflects an increase in the assumed probability of success for FebriDx’s US regulatory pathway to 95% from 80%.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) has secured firm commitments for a two-tranche placement to raise approximately A$91.5 million before costs, paving the way for a Final Investment Decision (FID) on Stage 1 construction of its Kangankunde Rare Earths Project in Malawi.
The institutional placement attracted significant demand from new Australian and offshore investors, exceeding the targeted raise. The board’s FID follows Lindian’s recently announced strategic partnership with Iluka Resources Ltd, which includes a binding long-term offtake agreement and project debt funding.